Until now focused on evaluation in patients (they developped several tools and evaluation methods of neuromuscular function) Jean-Yves Hogrel and his team recently have extended their area to in vivo evaluations in animals.
How long have you worked on in vivo evaluations in animals?
It is a fairly new area for me. I’ve been doing it for about 3 years. The first requests were from Genethon research groups that carried out many in vitro evaluations at the time and a few evaluations of general motor skills in the mouse. At their request, we have developed a non-invasive evaluation system of the flexion and extension strength in the mouse ankle to monitor animals.
What is the significance of this type of evaluation?
It is very powerful from a methodological point of view to follow the same animal during treatment, with non-invasive methods that are the least traumatic as possible. Since we cannot ask the animal to make voluntary contractions, we anaesthetize it and mechanically stimulate the nerve to trigger a muscle contraction in which we want to measure the force. This type of longitudinal follow-up preserves animals and increases the methodological robustness of the studies: each mouse is its own control. However, we also keep in mind that for a given function, there is not necessarily a direct link between the measured force and the activity of the animal: force is an interesting but insufficient indicator.
Moreover, from an experimental viewpoint, we encounter the same problems as in any other context of force measurement: feasibility, repeatability (there is little difference in measurements with identical evaluator, device and location), reproducibility (there is little difference in measurements with varying evaluator, device and location), sensitivity to change (or when changes in the observed force is due to the treatment rather than variability, either individual or in a given group of mice). As for acceptability, it does not pose a problem in animals.
Can you explain your major ongoing projects?
At the Institute, for example, Yves Fromes is working on a hamster model of delta-sarcoglycanopathy. Valérie Decostre is developing the device: she is working on the operating instructions and will begin a study of reproducibility in a dozen animals.
We also have a research project in the mouse on myotonic dystrophy with a team from Quebec and Geneviève Gourdon’s team. We will develop an evaluation method for a mouse model of myotonic dystrophy. The idea, for research but also for industry, is to have a tool that is as simple as possible and foremost, non-invasive.